Endocrine MPA enhances the effects of TAC chemotherapy on improvement of prognosis and increase in long-term survival rates for patients with endometrial cancer

Abstract

Abstract. The aim of the present study was to investigate the effect of taxol, adriamycin and carboplatin (TAC) chemotherapy combined with endocrine medroxyprogesterone acetate (MPA) therapy for the treatment of patients with endometrial cancer. A retrospective analysis of 124 patients with endometrial cancer was performed by dividing the cohort into an experimental and control group. The 64 patients in the experimental group received TAC and MPA chemotherapy, whereas the 60 patients in the control group were treated with TAC chemotherapy only. Tissue samples scraped from the uterus were used to extract the total proteins and RNAs for the western blot and reverse transcription-quantitative polymerase chain reaction analyses, respectively. All the patients were followed up for 20-45 months, during which time prognostic data, and one-to three-year survival rates were recorded and compared. The rate of recurrence or metastasis was significantly lower in the experimental group compared with that in the control group (P<0.05) and the three-year survival rate of the experimental group was significantly higher than that of the control group (P<0.05). Furthermore, the mean metastasis-associated 1 (MTA1) protein and RNA expression levels were significantly lower in the experimental group compared with the control group (P<0.05), exhibiting ~30 and ~15% of the levels in the control group, respectively. Therefore, a treatment strategy of TAC chemotherapy combined with endocrine MPA therapy appears to effectively improve the prognosis and increase the long-term survival rates of patients with endometrial cancer. Such an enhancing effect may be mediated by the transcriptional downregulation of MTA1 expression. IntroductionEndometrial cancer is a common type of malignant gynecological disease that predominantly occurs in post-menopausal females, aged 50-60 years. It accounts for 20-30% of cases of female cancer, with the incidence rate demonstrating an increasing trend in recent years (1). Tumors in endometrial cancer patients at clinical stages I/II exhibit a low degree of differentiation and invasive ability, therefore, good results can be obtained using surgical intervention. By contrast, tumors in patients at stages III/IV exhibit a higher degree of malignancy and differentiation, therefore, surgical treatments are only able to reduce tumor volume. Instead, adjuvant endocrine therapy, radiotherapy, and chemotherapy are typically administered for patients at stages III and IV to effectively improve the survival rate (2-4).The taxol, adriamycin and carboplatin (TAC) chemotherapy regimen has gradually been utilized for the treatment of patients with advanced endometrial cancer. Compared with the traditional adriamycin/cisplatin and cyclophosphamide/adriamycin/cisplatin regimens, the effect of the TAC regimen is more pronounced, causing fewer side effects in patients. In particular, TAC exhibits lower hematological toxicity, thus, resulting in more comprehensive treatment and improved recovery for patients (5).Endocrine thera...

Forkhead-box A1 induces cell senescence in endometrial cancer by regulating p16INK4a

“…In 2015, in the US alone, 54,870 women were newly diagnosed with EC and 10,170 may die of this disease (1). Hysterectomy with or without adjuvant whole pelvic radiation is the standard treatment; however, 30% of EC cases are not diagnosed until regional or distant metastasis has developed, resulting in a poorer outcome (2). Therefore, identification of additional molecular mechanisms associated with tumorigenesis and progression of EC, and the discovery of novel diagnostic and prognostic markers for EC are critical for making informed treatment decisions.…”